Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06822855 | Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma(LH_BIO) | recruiting | — | 755 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT05100056 | A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma(BV-MAZOVIA) | recruiting | — | 70 | TakedaINDUSTRY | 1 | May 27, 2026 |
| clinicaltrials |
| NCT00846742 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma | active not recruiting | Phase 2 | 88 | St. Jude Children's Research HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06812858 | PD-1 Inhibitors Maintenance for cHL Post-autoHCT | recruiting | Phase 2 | 83 | St. Petersburg State Pavlov Medical UniversityOTHER | 2 | May 22, 2026 | clinicaltrials |
| NCT06098430 | Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) | recruiting | — | 100 | St. Jude Children's Research HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07575893 | CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma(REACH-CD30) | not yet recruiting | Phase 1 | 12 | New York Medical CollegeOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT01790152 | Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | recruiting | — | 420 | Children's Oncology GroupNETWORK | 4 | May 18, 2026 | clinicaltrials |
| NCT02797470 | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 11 | AIDS Malignancy ConsortiumNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT05355051 | A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma | recruiting | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05404945 | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | active not recruiting | Phase 2 | 24 | University of VirginiaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | recruiting | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT01703949 | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma | active not recruiting | Phase 2 | 28 | University of WashingtonOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT01920932 | Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma | active not recruiting | Phase 2 | 77 | St. Jude Children's Research HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | recruiting | N/A | 25 | Jessica Mezzanotte SharpeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03057795 | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma | active not recruiting | Phase 2 | 62 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05949931 | Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma | recruiting | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT00131014 | Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies | recruiting | — | 1,500 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05550948 | Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer | active not recruiting | N/A | 44 | St. Jude Children's Research HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06377566 | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | recruiting | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04134325 | Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma | active not recruiting | Early Phase 1 | 10 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06617286 | CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 21 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01890486 | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05481437 | A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma | recruiting | — | 8 | TakedaINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06487624 | An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors | recruiting | Phase 1 | 50 | FBD Biologics LimitedINDUSTRY | 3 | Apr 13, 2026 | clinicaltrials |
| NCT06923397 | Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial | recruiting | N/A | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05544968 | Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies | recruiting | Phase 1 | 42 | Medical College of WisconsinOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07234487 | Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL | recruiting | Phase 2 | 178 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06915246 | A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma | recruiting | Phase 2 | 49 | VIVUS LLCINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04726501 | CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma | active not recruiting | Phase 4 | 200 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06563245 | Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment | recruiting | Phase 2 / Phase 3 | 96 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | recruiting | Phase 2 | 216 | City of Hope Medical CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05502250 | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission(HOVON164HL) | active not recruiting | Phase 2 | 75 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 3 | Mar 6, 2026 | clinicaltrials |
| NCT05540340 | A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT01788839 | Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | recruiting | — | 475 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT01555892 | Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE(GRALE) | recruiting | Phase 1 | 136 | Baylor College of MedicineOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06831370 | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India | recruiting | Phase 4 | 124 | TakedaINDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03033914 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | active not recruiting | Phase 1 / Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 17, 2026 | clinicaltrials |
| NCT06484920 | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL | recruiting | Phase 2 | 24 | Rita AssiOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT01192464 | EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma(CARCD30) | active not recruiting | Phase 1 | 18 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04067037 | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma | active not recruiting | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05180097 | Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 | 84 | Canadian Cancer Trials GroupNETWORK | 2 | Feb 2, 2026 | clinicaltrials |
| NCT05839210 | Lifestyle Intervention of Food and Exercise for Lymphoma Survivors(LIFE-L) | recruiting | N/A | 140 | University of MiamiOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07374068 | Prognostic Model of Elderly Hodgkin Lymphoma in China | active not recruiting | — | 400 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07356882 | European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma(EURHOLY) | recruiting | — | 400 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT01483664 | Communication Skills Intervention to Promote Transition Into Survivorship | active not recruiting | — | 314 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 29, 2026source: clinicaltrials